Abstract | BACKGROUND: METHODS: A total of 20 patients with histologically proven primary biliary cirrhosis were enrolled. Patients had early stage primary biliary cirrhosis as serum bilirubin levels were normal and the Mayo risk score 4.2 +/- 0.5. Group 1 received 600, 1200 and 1800 mg/day of ursodeoxycholic acid; group 2 received 900, 1500 and 2100 mg/day. The order of periods was randomized. Each treatment period lasted 3 months followed by a further 3 months during which a standard dose of ursodeoxycholic acid was given. At the end of each treatment period, liver tests were evaluated, and biliary bile acid pattern of duodenal bile was determined using high pressure liquid chromatography. RESULTS: CONCLUSIONS:
|
Authors | E Roda, F Azzaroli, G Nigro, F Piazza, F Jaboli, F Ferrara, S Liva, S Giovanelli, A Miracolo, A Colecchia, D Festi, C Mazzeo, L Bacchi, A Roda, G Mazzella |
Journal | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
(Dig Liver Dis)
Vol. 34
Issue 7
Pg. 523-7
(Jul 2002)
ISSN: 1590-8658 [Print] Netherlands |
PMID | 12236487
(Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Bile Acids and Salts
- Biomarkers
- Cholagogues and Choleretics
- Ursodeoxycholic Acid
- Transaminases
- Alkaline Phosphatase
|
Topics |
- Alkaline Phosphatase
(drug effects)
- Bile Acids and Salts
(metabolism)
- Biomarkers
(blood)
- Cholagogues and Choleretics
(administration & dosage)
- Dose-Response Relationship, Drug
- Female
- Humans
- Liver
(drug effects, metabolism)
- Liver Cirrhosis, Biliary
(drug therapy, metabolism)
- Liver Function Tests
- Male
- Time Factors
- Transaminases
(drug effects)
- Treatment Outcome
- Ursodeoxycholic Acid
(administration & dosage)
|